Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder
- PMID:15107657
- DOI: 10.1097/00004850-200405000-00005
Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder
Erratum in
- Int Clin Psychopharmacol. 2004 Jul;19(4):255
Abstract
Escitalopram is the S-enantiomer of citalopram. In this study, we compared the efficacy of equivalent dosages of escitalopram and citalopram in the treatment of moderate to severe major depressive disorder (MDD), based on data from two, pooled, randomized, double-blind, placebo-controlled studies of escitalopram in which citalopram was the active reference. The primary efficacy parameter was the mean change from baseline in the Montgomery Asberg Depression Rating Scale (MADRS) total score. Significant differences in favour of escitalopram were observed for the MADRS [P<0.05, observed cases (OC)/last observation carried forward (LOCF)] and Clinical Global Improvement-Severity of Illness scores (CGI-S; P<0.05, OC/LOCF). Escitalopram separated from placebo at week 1 on the primary efficacy parameter, whereas citalopram first separated from placebo at week 6. An analysis of time to response showed that escitalopram-treated patients responded significantly faster to treatment than citalopram-treated patients (P<0.01). More patients responded to and achieved remission with escitalopram than to citalopram (P<0.05, OC). The HAMD scale was only used in the fixed-dose study, where escitalopram-treated patients had a significant reduction in HAMD-17 total score at week 8 compared to citalopram-treated patients (P<0.05, OC/LOCF). In the pooled subpopulation of severely ill patients (MADRS> or = 30), escitalopram-treated patients showed greater improvement than citalopram-treated patients (P<0.05, LOCF/OC). Escitalopram showed consistently superior efficacy compared to citalopram in the treatment of moderate to severe MDD on all efficacy parameters, and was similarly well tolerated.
Similar articles
- Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV.Yevtushenko VY, et al.Clin Ther. 2007 Nov;29(11):2319-32. doi: 10.1016/j.clinthera.2007.11.014.Clin Ther. 2007.PMID:18158074Clinical Trial.
- Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.Khan A, Bose A, Alexopoulos GS, Gommoll C, Li D, Gandhi C.Khan A, et al.Clin Drug Investig. 2007;27(7):481-92. doi: 10.2165/00044011-200727070-00005.Clin Drug Investig. 2007.PMID:17563128Clinical Trial.
- [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].Azorin JM, Llorca PM, Despiegel N, Verpillat P.Azorin JM, et al.Encephale. 2004 Mar-Apr;30(2):158-66. doi: 10.1016/s0013-7006(04)95427-9.Encephale. 2004.PMID:15107719Clinical Trial.French.
- Escitalopram : a review of its use in the management of major depressive and anxiety disorders.Waugh J, Goa KL.Waugh J, et al.CNS Drugs. 2003;17(5):343-62. doi: 10.2165/00023210-200317050-00004.CNS Drugs. 2003.PMID:12665392Review.
- [Escitalopram for treatment of major depressive disorder in adults].Llorca PM, Brousse G, Schwan R.Llorca PM, et al.Encephale. 2005 Jul-Aug;31(4 Pt 1):490-501. doi: 10.1016/s0013-7006(05)82410-8.Encephale. 2005.PMID:16389716Review.French.
Cited by
- Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study.Ou JJ, Xun GL, Wu RR, Li LH, Fang MS, Zhang HG, Xie SP, Shi JG, Du B, Yuan XQ, Zhao JP.Ou JJ, et al.Psychopharmacology (Berl). 2011 Feb;213(2-3):639-46. doi: 10.1007/s00213-010-1822-y. Epub 2010 Mar 26.Psychopharmacology (Berl). 2011.PMID:20340011Clinical Trial.
- Demystifying racemic natural products in the homochiral world.Bitchagno GTM, Nchiozem-Ngnitedem VA, Melchert D, Fobofou SA.Bitchagno GTM, et al.Nat Rev Chem. 2022;6(11):806-822. doi: 10.1038/s41570-022-00431-4. Epub 2022 Oct 14.Nat Rev Chem. 2022.PMID:36259059Free PMC article.Review.
- Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action.Zhong H, Haddjeri N, Sánchez C.Zhong H, et al.Psychopharmacology (Berl). 2012 Jan;219(1):1-13. doi: 10.1007/s00213-011-2463-5. Epub 2011 Sep 8.Psychopharmacology (Berl). 2012.PMID:21901317Review.
- The interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse.Jacobsen JP, Plenge P, Sachs BD, Pehrson AL, Cajina M, Du Y, Roberts W, Rudder ML, Dalvi P, Robinson TJ, O'Neill SP, Khoo KS, Morillo CS, Zhang X, Caron MG.Jacobsen JP, et al.Psychopharmacology (Berl). 2014 Dec;231(23):4527-40. doi: 10.1007/s00213-014-3595-1. Epub 2014 May 9.Psychopharmacology (Berl). 2014.PMID:24810106Free PMC article.
- Comparative efficacy of escitalopram in the treatment of major depressive disorder.Ali MK, Lam RW.Ali MK, et al.Neuropsychiatr Dis Treat. 2011;7:39-49. doi: 10.2147/NDT.S12531. Epub 2011 Feb 1.Neuropsychiatr Dis Treat. 2011.PMID:21430793Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources